• LAST PRICE
    5.2950
  • TODAY'S CHANGE (%)
    Trending Down-0.0050 (-0.0943%)
  • Bid / Lots
    5.1800/ 10
  • Ask / Lots
    5.3900/ 3
  • Open / Previous Close
    5.3600 / 5.3000
  • Day Range
    Low 5.1500
    High 5.6000
  • 52 Week Range
    Low 4.1700
    High 11.9900
  • Volume
    12,524
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.3
TimeVolumePRTG
09:32 ET8765.36
09:35 ET5935.25
09:53 ET14585.35
09:55 ET21005.5
10:00 ET1005.5017
10:04 ET1005.31
10:06 ET8005.285
10:11 ET5005.1875
10:13 ET1005.26
10:24 ET1005.16
10:27 ET3005.1619
10:36 ET10005.15
10:44 ET5005.2055
10:54 ET5115.2285
11:02 ET10005.25
11:09 ET1005.25
11:27 ET2845.2
11:34 ET1005.295
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPRTG
Portage Biotech Inc
90.4M
-5.3x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
90.4M
-2.3x
---
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
90.2M
-3.6x
---
United StatesNCNA
NuCana PLC
72.0M
-1.9x
---
United StatesIMUX
Immunic Inc
91.8M
-0.8x
---
United StatesINZY
Inozyme Pharma Inc
84.8M
-1.1x
---
As of 2023-01-27

Company Information

Portage Biotech Inc. is a Canada-based clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Its portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

Contact Information

Headquarters
47 Avenue Rd Suite 200TORONTO, ON, Canada M5R 2G3
Phone
416-929-1806
Fax
416-929-6612

Executives

Chairman of the Board, Chief Executive Officer
Ian Walters
Chief Financial Officer
Allan Shaw
Chief Scientific Officer
Robert Kramer
Vice President - Development
Justin Fairchild
Vice President - Project Management and Operations
Steven Innaimo

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$90.4M
Revenue (TTM)
$0.00
Shares Outstanding
17.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.00
Book Value
$9.08
P/E Ratio
-5.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.